Introduction {#sec1_1}
============

Oxidative stress, defined as an imbalance of pro-oxidant and antioxidant exposures wherein the effects of the pro-oxidants exceed the effects of the antioxidants, is a potential source of cellular damage \[[@B1]\]. Oxidative stress is closely related to, and is both a cause and consequence of, inflammation. Oxidative stress has pro-inflammatory effects through activation of nuclear factor-kappa B, which increases the expression of chemokines, cytokines, and cell adhesion molecules \[[@B2], [@B3], [@B4], [@B5]\].

Oxidative stress and inflammation are proposed mechanisms of nonspecific kidney injury and progressive kidney failure \[[@B6], [@B7]\]. Studies have found that chronic kidney disease (CKD) is associated with increased levels of reactive oxygen and nitrogen species \[[@B6], [@B7], [@B8], [@B9]\]; this occurs in early CKD and may be a factor in a progressive decline in the glomerular filtration rate and vascular complications \[[@B8], [@B10], [@B11]\]. Further, individuals with CKD and compromised nutritional status show more signs of oxidative stress than well-nourished individuals \[[@B12], [@B13]\].

There is evidence that diet, medication, and lifestyle are important exogenous sources contributing to the body\'s oxidative balance \[[@B6]\]. However, it has been difficult to show associations between individual dietary antioxidants and kidney injury, as the effects may be modest, correlated, and may involve biological interactions across multiple factors \[[@B14]\]. Evidence is emerging that a dietary score based on multiple oxidative stress-influencing nutrients may capture the complex interactions between individual pro- and antioxidants, and is associated with disease states \[[@B6], [@B15], [@B16], [@B17], [@B18]\], such as CKD \[[@B19]\].

It was previously reported that a higher oxidative balance score (OBS), defined by a composite estimate of the overall pro- and antioxidant exposure status in an individual, is associated with lower prevalence of CKD among participants of the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study \[[@B19]\]. After multivariable adjustment, prevalent CKD remained associated with decreased OBS; and while the association with end-stage renal disease was not statistically significant, a reduced risk of end-stage renal disease was suggested with higher levels of OBS. It was also previously reported that REGARDS participants with higher OBS were more likely to have favorable levels of surrogate markers for inflammation, such as decreased C-reactive protein (CRP) and lower total white blood cell (WBC) count \[[@B20]\]. Similar observations have been reported elsewhere \[[@B4]\].

This analysis extends upon previous findings \[[@B4], [@B19], [@B20]\] by examining additional biomarkers of inflammation beyond CRP and WBC that might provide clues as to different pathways of inflammation, and does so in the context of CKD. The purpose of this study is to examine the association between OBS and a wider range of inflammatory biomarkers, and whether this association differs in persons with and without CKD.

Methods {#sec1_2}
=======

Study Design {#sec2_1}
------------

The REGARDS study is a national, population-based prospective cohort study that aims to examine reasons for variation in stroke incidence in the United States. Recruitment and data collection are described in detail elsewhere \[[@B21]\]. Briefly, between January 2003 and October 2007, 30,239 volunteers aged 45 years and older were randomly selected and recruited, with planned equal recruitment of men and women. There was oversampling of African Americans and residents of the 8 southeastern states with a higher stroke mortality than in the rest of the US. The 8 states are divided into the stroke "buckle" (coastal plain regions of Georgia, North Carolina, and South Carolina) and the "belt" (the remaining area of Georgia, North Carolina, and South Carolina, plus Mississippi, Alabama, Tennessee, Louisiana, and Arkansas) \[[@B22]\].

Trained personnel used a computer-assisted telephone survey to collect data on demographic factors (e.g., age, race, sex), socioeconomic factors (e.g., household income, education, marital status), and medical history. Next, a health professional visited the participants\' homes to collect anthropomorphic variables as well as blood and urine samples. The REGARDS study was approved by the institutional review boards of the participating institutions, and all participants provided written informed consent before completion of the in-home study visit.

The 1998 Block Food Frequency Questionnaire (Block 98 FFQ; Nutrition Quest, Berkeley, CA, USA) was left with the participants to be self-administered and returned. The FFQ is comprised of 107 items that assess dietary intake over the previous year. The Block 98 FFQ has been extensively validated using multiple food records in diverse populations in the United States, and reliably estimates the intake of nutrients \[[@B23], [@B24], [@B25], [@B26]\]. The FFQ has been described in detail elsewhere \[[@B22], [@B27]\]. Completed FFQs were scanned and sent to Nutrition Quest^TM^ (Berkeley, CA, USA) for the analysis of the nutrition content. The dietary data collected using the FFQ were used to calculate the OBS.

The data for the present analysis come from a case-cohort study designed to investigate biomarkers of stroke and cognitive impairment within the REGARDS study \[[@B28], [@B29]\]. The cohort random sample included 1,104 participants selected using stratified random sampling to ensure sufficient representation of high-risk groups (50% blacks, 50% whites; 50% women, 50% men) and age groups (20% aged 45--54 years, 20% aged 55--64 years, 25% aged 65--74 years, 25% aged 75--84 years, and 10% aged ≥85 years).

Population {#sec2_2}
----------

From the cohort random sample (*n* = 1,104), we excluded 362 participants who did not have data from the Block FFQ or were missing data on OBS components (Fig. [1](#F1){ref-type="fig"}). We also excluded 23 participants who did not have data on any of the 7 biomarkers of inflammation, and 37 participants with missing albumin/creatinine ratio (ACR) or missing estimated glomerular filtration rate (eGFR). A total of 682 participants were included in the final analysis. Excluded individuals were more likely to be black, diabetic, have a lower income, and have a lower level of education.

Oxidative Balance Scores {#sec2_3}
------------------------

The exposure of interest, OBS, incorporates information on 11 a priori defined pro- and antioxidant factors (Table [1](#T1){ref-type="table"}) \[[@B15], [@B30]\]. The pro-oxidants included were polyunsaturated fatty acid, total (food and supplement) iron, and use of alcohol. The antioxidants considered were total selenium, total vitamin C, total vitamin E, total α-carotene, total β-carotene, lutein, lycopene, and cryptoxanthin \[[@B15]\]. Smoking, which was included in the original OBS, was excluded here as it is a strong risk factor for CKD \[[@B31], [@B32], [@B33], [@B34], [@B35], [@B36]\]; furthermore, the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and aspirin was excluded as well because avoidance of NSAIDs is recommended for most patients with CKD \[[@B37], [@B38], [@B39], [@B40]\].

Continuous dietary variables were adjusted for total energy intake via the residual method of Willett and Stampfer \[[@B41]\]. The continuous dietary variables representing pro-oxidants (polyunsaturated fatty acid and iron) and antioxidants (selenium, vitamin C, vitamin E, α-carotene, β-carotene, lutein, lycopene, and cryptoxanthin) were categorized as low, medium, and high based on each exposure\'s sex-specific tertiles. For antioxidants, the first through third tertiles were assigned 0--2 points, while pro-oxidants were scored in the reverse (0 points for the third tertile and 2 points for the first tertile). As for alcohol consumption, nondrinkers received 2 points, moderate drinkers (1--7 drinks/week for women and 1--14 drinks/week for men) received 1 point, and heavy drinkers (\> 7 drinks/week for women and \> 14 drinks/week for men) received 0 points (Table [1](#T1){ref-type="table"}). The points for each component were summed to calculate the overall OBS where lower (less favorable) and higher (more favorable) total scores indicate predominance of pro- and antioxidant exposures, respectively.

Biomarkers of Inflammation {#sec2_4}
--------------------------

Biomarkers of inflammation under study were interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), fibrinogen, CRP, WBC count, and cystatin C (Cys C). Blood was collected during the in-home examination after an 8- to 10-h fast; sample processing and validation of the laboratory data have been previously reported \[[@B42]\]. CRP and Cys C were measured by particle-enhanced immunonephelometry using the BNII nephelometer (N High Sensitivity CRP, N Latex Cystatin C; Dade Behring) \[[@B43]\] and WBC count was measured using an automated analyzer (Beckman Coulter, Inc., Fullerton, CA, USA) \[[@B44]\] at the University of Vermont Laboratory for Clinical Biochemistry Research.

IL-6, IL-8, IL-10, and fibrinogen were measured in the cohort random sample in August 2012 at the University of Vermont Laboratory for Clinical Biochemistry Research. IL-6 was measured by ultra-sensitive ELISA (Quantikine HS Human IL-6 Immunoassay; R and D Systems, Minneapolis, MN, USA), IL-8 was measured by the Human Serum Adipokine Panel B LINCOplex Kit (Linco Research, Inc.; St. Charles, MO, USA), IL-10 was measured using the Milliplex MAP Human Cardiovascular Disease (CVD) Panel 3 (Millipore Corporation; Billerica, MA, USA) run as a single-plex assay, and fibrinogen was measured using the BNII nephelometer (N Antiserum to Human Fibrinogen; Siemens Healthcare Diagnostics, Deerfield, IL, USA).

Chronic Kidney Disease {#sec2_5}
----------------------

CKD was defined as the joint distribution of ACR and eGFR as described in current clinical practice guidelines \[[@B45]\] (eGFR \< 60 mL/min/1.73m^2^ according to the Chronic Kidney Disease Epidemiology Collaboration equation \[[@B46]\] or albuminuria ≥30 mg/g).

Covariates {#sec2_6}
----------

Age, sex, race, smoking, physical activity, income, educational attainment, aspirin use, statin use, NSAID use, and diabetes were self-reported. Region was classified as stroke belt, stroke buckle, or nonbelt. Energy and protein intakes were obtained from the FFQ and analyzed as continuous variables. Weight (kilograms), height (meters), and waist circumference (centimeters) were measured during the in-home visit following a standardized protocol. BMI was calculated as weight (kg)/height (m^2^). Waist circumference was measured with a tape measure at a point midway between the lowest rib and the iliac crest with the subject standing.

Statistical Analyses {#sec2_7}
--------------------

All data analyses were performed using SAS 9.4 (Cary, NC, USA). Characteristics of the study population were reported overall and across OBS intervals. Differences in characteristics across the OBS intervals were tested using analysis of variance for normally distributed continuous variables, Kruskal-Wallis test for skewed variables, and χ^2^ statistics for categorical variables.

OBS was the independent variable of interest and was treated as a continuous variable or in intervals (interval 1 was set to range in score from 0 to 5, interval 2 from 6 to 9, interval 3 from 10 to 13, interval 4 from 14 to 17, and interval 5 from 18 to 22). The dependent variables of interest were IL-6, IL-8, IL-10, fibrinogen, CRP, WBC count, and Cys C; dependent variables that were not normally distributed were log-transformed to meet the assumptions of normality. The first OBS interval, representing a predominance of pro-oxidants, was used as the reference group when the OBS distribution was divided into intervals.

A set of potential confounding variables was identified a priori, based on previously published literature and biological plausibility, for consideration in multivariable linear regression models used to estimate the association between OBS and biomarkers of inflammation. The final model was selected after removing covariates from the full model that did not satisfy our a priori change-in-estimate criterion of 10%. The final model, with weighting to account for the sampling design of the cohort random sample, was adjusted for age, sex, race, region, smoking status, BMI, protein intake, energy intake, NSAID, aspirin, and statin use. An interaction term between OBS and CKD (yes/no) was included in models to determine if the associations between OBS and biomarkers of inflammation were comparable for individuals with and without CKD. The trend tests for OBS (from lower to higher intervals) were conducted in final multivariable models by assigning the median value from each interval of OBS and modeling this as a continuous variable.

Results {#sec1_3}
=======

There were 682 participants included in the analysis. On average, participants were 66.9 (standard deviation: 11.9) years old, 51.3% were women, and 56.3% were white. Participants, on average, were overweight (BMI: 28.7), and 57% were hypertensive while a little less than one-fifth (19.7%) had been diagnosed with diabetes mellitus. Median eGFR was 87 mL/min/1.73m^2^ (interquartile range: 70--99 mL/min/1.73m^2^) and median ACR was 7.3 mg/g (interquartile range: 4.5--14.6 mg/g); 22.4% of the sample had CKD (Table [2](#T2){ref-type="table"}).

OBS ranged from 1 to 21 points and the mean score was 11.7 (standard deviation: 3.5). Individuals with higher OBS were generally older (61.3 years in interval 1 vs. 64.0 years in interval 5; *p* = 0.02). Current smokers were more likely to be in the lowest interval of OBS (31.8% in interval 1 vs. 21.9% in interval 5; *p* \< 0.001). Those in the lowest OBS interval reported greater energy intakes than those in a higher OBS interval (2,052 kcal in interval 1 vs. 1,960 kcal in interval 5; *p* \< 0.001) (Table [2](#T2){ref-type="table"}).

The Spearman correlation coefficients between OBS and biomarkers of inflammation ranged from *r* = −0.09 to 0.01, with only CRP (*r* = −0.09; *p* = 0.02) and IL-6 (*r* = −0.08; *p* = 0.04) being significantly correlated with OBS. Among the biomarkers of inflammation, IL-6 and CRP were strongly correlated with one another (*r* = 0.50, *p* \< 0.001), as were fibrinogen and CRP (*r* = 0.51, *p* \< 0.001) (online suppl. Table [S1](#S1){ref-type="supplementary-material"}; see [www.karger.com/doi/10.1159/000490499](http://www.karger.com/doi/10.1159/000490499) for all online suppl. material).

Unadjusted models of the association between OBS and biomarkers of inflammation were largely null, except for IL-6 and CRP (online suppl. Table [S2](#S1){ref-type="supplementary-material"}). In models adjusted for age, sex, race, region, smoking status, BMI, protein intake, energy intake, NSAID, aspirin, and statin use, associations between OBS and IL-6, and OBS and CRP were attenuated but remained significant in the continuous models (Table [3](#T3){ref-type="table"}). For every 5-unit increase in OBS, the IL-6 concentration was −6.4% lower (95% CI: −11.9, −0.5; *p* = 0.03). Comparing the concentration in interval 5 to that in interval 1, the IL-6 concentration was −10.1% lower (95% CI: −33.5, 21.6; *p* trend: 0.06). For every 5-unit increase in OBS, CRP concentration was −15.3% lower (95% CI: −25.6, −3.6; *p* = 0.01). CRP concentration was −35.7% lower (95% CI: −65.8, 21.1; *p* trend: 0.05) when comparing the concentration in interval 5 to that in interval 1.

In unadjusted models, there was a difference in the associations of OBS with IL-6, fibrinogen, CRP, and Cys C by CKD status. The unadjusted association of OBS and IL-10 was suggestive of a difference by CKD status, though not statistically significant (online suppl. Table [S3](#S1){ref-type="supplementary-material"}).

In adjusted models, interaction by CKD was observed between OBS and IL-6 (*p* = 0.03), OBS and IL-10 (*p* = 0.03), and OBS and Cys C (*p* \< 0.001) (Table [4](#T4){ref-type="table"}). Among those with CKD, the association between a 5-unit increase in OBS and IL-6 concentration was virtually null (--0.1%, 95% CI: −13.5, 15.4; *p* = 0.9); IL-6 concentration was −10.7% lower (95% CI: −16.3, −4.7; *p* = 0.001) for every 5-unit increase in OBS among those without CKD. These trends persisted across intervals of OBS exposure (*p* trend: 0.5 among those with CKD; *p* trend: 0.004 among those without CKD).

IL-10 concentration was −1.3% lower (95% CI: −26.7, 32.9; *p* = 0.9) for every 5-unit increase in OBS among those with CKD, while the IL-10 concentration was 7.5% higher (95% CI: −3.7, 19.9; *p* = 0.2) for every 5-unit increase in OBS among those without CKD. Similar trends were observed across intervals of OBS exposure (*p* trend: 0.9 among those with CKD; *p* trend: 0.3 among those without CKD).

Among those with CKD, Cys C was 1.7% higher (95% CI: −6.6, 10.7; *p* = 0.7) for every 5-unit increase in OBS; Cys C concentration was −1.1% lower (95% CI: −3.1, 1.0; *p* = 0.3) for every 5-unit increase in OBS among those without CKD. These trends persisted across intervals of OBS exposure (*p* trend: 0.6 among those with CKD; *p* trend: 0.2 among those without CKD).

While there was no interaction present for the association of OBS with IL-8 by CKD status, examining differences in the associations of OBS and inflammatory markers was an a priori objective. OBS was positively associated with IL-8 among those with CKD; IL-8 was 14.7% higher (95% CI: 0.3, 31.1; *p* = 0.04) for every 5-unit increase in OBS, and these trends persisted across intervals of OBS exposure (*p* trend: 0.05 among those with CKD).

Discussion {#sec1_4}
==========

We found that a higher OBS, reflecting an increased antioxidant balance, was associated with lower IL-6 levels and lower CRP levels, but not other studied biomarkers of inflammation. We also examined the associations between OBS and biomarkers of inflammation stratified by CKD (defined as eGFR \< 60 mL/min/1.73m^2^ or albuminuria ≥30 mg/g \[[@B45]\]), and found that there is significant interaction by CKD of the association between OBS and IL-6, OBS and IL-10, and OBS and Cys C.

Overall, among those with CKD, there was an inconsistent pattern of associations between OBS and biomarkers of inflammation. The association between OBS and IL-6 was null among those with CKD, whereas higher OBS was associated with lower IL-6 among those without CKD. Among those without CKD, there was higher IL-10 for higher OBS (unlike other biomarkers of inflammation, higher levels of IL-10 are favorable), compared to those with CKD. Additionally, it was observed that higher OBS was associated with higher Cys C among those with CKD whereas higher OBS was associated with lower Cys C among those without CKD. Lastly, we found that among those with CKD, OBS was positively associated with IL-8 (a pro-inflammatory cytokine), a finding that was not in the expected direction. This association could potentially be due to changes in diet participants have made to manage their disease. Alternatively, it is possible that some participants with CKD were not prescribed diet changes, particularly in the early stages of CKD, and continued to consume a high fruit and vegetable diet (high in antioxidants). It is conceivable that such a diet in CKD participants might have the opposite of intended effect, due to the presence of nutrients that increase the workload on the kidneys and lead to increased inflammation.

We found that the greater the shift from pro- to antioxidant exposures (low to high OBS), the more favorable the levels of IL-6 and CRP. As might be expected since IL-6 induces CRP production \[[@B47]\], IL-6 and CRP were highly correlated and similarly associated with OBS. To our knowledge, this is the first study to examine the association between the balance of pro- and antioxidants, as measured by OBS, and biomarkers of inflammation among individuals with and without CKD. Previous studies in the REGARDS cohort have found an association between OBS and CRP \[[@B4], [@B20]\], and this finding is confirmed in this smaller subset of the REGARDS study. A previous study also found an association between OBS and WBC count, although that was not replicated in the present study \[[@B20]\]. While this is not the first study to examine the association between OBS and certain biomarkers of inflammation, it is the first to examine OBS with a wider panel of biomarkers of inflammation and stratified by CKD.

Additionally, to our knowledge, this study is the first to examine the association between OBS and Cys C. Cys C is a biomarker of inflammation as well as a marker of renal function \[[@B48]\]. As might be anticipated, this study found highly significant interaction by presence or absence of CKD in the association between OBS and Cys C. As with other biomarkers of inflammation, the association between OBS and Cys C was as predicted among those without CKD (higher OBS associated with more favorable levels of biomarkers of inflammation). The association between OBS and Cys C was less clear among those with CKD. While Cys C levels were significantly lower in intervals 2, 3, and 4 compared to interval 1, Cys C levels were almost 2% higher for every 5-unit increase in OBS in continuous models.

This study follows up on a previous study in the REGARDS cohort that found that a higher OBS is associated with a lower prevalence of CKD, though the decrease was modest (adjusted odds ratio: 0.93 \[95% CI: 0.86, 0.99\]) \[[@B19]\]. While no association was observed between OBS and CKD in adjusted models in this smaller subsample of the REGARDS study, there are a number of reasons for this. The present study uses an exclusively dietary OBS (NSAIDs and aspirin were not included in the OBS, but controlled for in the model instead), uses the residual method of energy adjustment \[[@B41]\] to evaluate OBS components in relation to total energy intake, and simply has a smaller sample size and therefore potentially lacks the power to detect a modest association.

One aim of this study was to determine if the effect of OBS on biomarkers of inflammation differed among those with and without CKD. We found that there was significant interaction by CKD in the IL-6, IL-10, and Cys C models with more pronounced associations observed among those without CKD, and some indication (though nonsignificant) that there was interaction by CKD in the fibrinogen model as well. It is plausible that the association of OBS with biomarkers of inflammation differs by CKD status due to a number of biologic changes that occur during CKD progression \[[@B6], [@B7], [@B8], [@B9], [@B10], [@B11], [@B12], [@B13]\]. While interaction by CKD status was seen for certain biomarkers of inflammation, there was potentially limited power to detect interaction by CKD status for some biomarkers of inflammation, as there were only 153 participants with CKD in our sample. Conversely, it is possible that no interaction was found for certain biomarkers of inflammation because it truly does not exist. Seven different biomarkers of inflammation were analyzed because each represents a particular mechanism and, therefore, we do not necessarily expect all 7 biomarkers to hold the same relationships. Ultimately, further studies are warranted to confirm whether the association of OBS and biomarkers of inflammation differs among those with and without CKD, and research in a cohort of CKD participants is particularly needed to understand the association of OBS with biomarkers of inflammation.

While this is cross-sectional data and the results must be interpreted with caution (e.g., we cannot assess causality), these findings suggest that interventions to improve oxidative balance in the diet might have different effects on inflammation among those with and without CKD. Among those without CKD, increasing antioxidant and decreasing pro-oxidant consumption in the diet could, based on these data, seemingly have the intended effect of lowering inflammation. Alternatively, based on this exploratory analysis, it seems as though the same approach would not be recommended among those with CKD. It should be noted that the CKD population in this study could be highly heterogeneous. Because this is cross-sectional data, we do not have information on the severity or duration of CKD, and some individuals may have made changes to their diet because of their CKD that could result in a lower OBS (e.g., eliminating potassium-rich foods would also eliminate some good sources of antioxidants such as oranges and tomatoes). Essentially, in complying with a renal diet that is low in sodium, potassium, and phosphorus, CKD participants may score lower in terms of OBS, though it is difficult to predict how this would impact the association of OBS with biomarkers of inflammation since severity of disease and diet compliance might confound the association. Future research utilizing prospective data is warranted to better understand the association between OBS and biomarkers of inflammation among those with CKD.

OBS has been validated previously. In the REGARDS cohort, OBS was associated with all-cause, cancer, and noncancer morality \[[@B49]\]. OBS has also been validated in a pooled case-control study of incident, sporadic colorectal adenoma \[[@B18]\], where it was found that OBS was also associated with circulating biomarkers of oxidative stress (F2-isoprostanes and CRP) \[[@B4]\].

Strengths of this study include the substantial covariate data available and multiple biomarkers of inflammation considered. Additionally, OBS provides a measure that sums the effects of pro- and antioxidant factors in the diet, and this "effect" or "balance" can be used to predict outcomes. Furthermore, by determining a priori the cutoffs for the components of OBS, subjectivity in measurement is reduced \[[@B6]\].

Limitations of this study include the possibility of misclassification due to self-reported data, mainly from the FFQ, which was used to determine the OBS. While dietary questionnaires like the FFQ are subject to recall bias and nutritional intake may be inaccurate, such questionnaires provide acceptable classification of nutrient intake on the population level \[[@B50], [@B51], [@B52]\]. Given that there were only 153 individuals with CKD, our ability to detect interaction by CKD status may have been limited. Lastly, individuals excluded due to missing data on OBS, CKD, or biomarkers of inflammation were more likely to be black, diabetic, have a lower income, and have a lower level of education, suggesting that selection bias may be a concern.

In conclusion, this study suggests that a higher OBS -- consistent with a greater shift from pro- to antioxidant exposures (low to high OBS) -- is associated with more favorable levels of biomarkers of inflammation, particularly among those without CKD.
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![Flowchart of participants in the REGARDS study who were included in the analysis. eGFR, estimated glomerular filtration rate; ACR, albumin/creatinine ratio.](nne-0008-0011-g01){#F1}

###### 

Dietary oxidative balance score (OBS) components[^a^](#T1F1){ref-type="table-fn"}

  ------------------------------------------------- -------------------------------------------------------------------------
  1\. Cryptoxanthin                                 0 = low (1st tertile), 1 = medium (2nd tertile), 2 = high (3rd tertile)
  2\. Alcohol                                       
   Female                                           0 = 8+ drinks/week, 1 = 1--7 drinks/week, 2 = \<1 drink/week
   Male                                             0 = 15+ drinks/week, 1 = 1--14 drinks/week, 2 = \<1 drink/week
  3\. PUFA                                          0 = high (3rd tertile), 1 = medium (2nd tertile), 2 = low (1st tertile)
  4\. Total iron[^b^](#T1F2){ref-type="table-fn"}   0 = high (3rd tertile), 1 = medium (2nd tertile), 2 = low (1st tertile)
  5\. Total vitamin C                               0 = low (1st tertile), 1 = medium (2nd tertile), 2 = high (3rd tertile)
  6\. Total α-carotene                              0 = low (1st tertile), 1 = medium (2nd tertile), 2 = high (3rd tertile)
  7\. Total β-carotene                              0 = low (1st tertile), 1 = medium (2nd tertile), 2 = high (3rd tertile)
  8\. Total vitamin E                               0 = low (1st tertile), 1 = medium (2nd tertile), 2 = high (3rd tertile)
  9\. Total selenium                                0 = low (1st tertile), 1 = medium (2nd tertile), 2 = high (3rd tertile)
  10\. Lutein                                       0 = low (1st tertile), 1 = medium (2nd tertile), 2 = high (3rd tertile)
  11\. Lycopene                                     0 = low (1st tertile), 1 = medium (2nd tertile), 2 = high (3rd tertile)
  ------------------------------------------------- -------------------------------------------------------------------------

PUFA, polyunsaturated fatty acid.

Low, medium, and high categories correspond to sex-specific 1st, 2nd, and 3rd tertiles, adjusted for total energy intake via the residual method.

Total, dietary and supplemental.

###### 

Characteristics of participants in the REGARDS cohort random sample by oxidative balance score (OBS) interval (higher intervals represent higher antioxidant exposure) (*n* = 682)

  Characteristic[^a^](#T2F1){ref-type="table-fn"}   All               OBS                                                                     
  ------------------------------------------------- ----------------- ----------------- ----------------- ----------------- ----------------- ----------------------------------------------
  *n*                                               682               22                161               272               195               32
  Age, years                                        66.9 (11.9)       61.3 (10.6)       65.9 (12.6)       67.0 (12.1)       68.7 (11.0)       64.0 (11.3)[^b^](#T2F2){ref-type="table-fn"}
  Female, %                                         51.3              54.6              49.7              51.1              50.8              62.5
  White, %                                          56.3              40.9              59.0              55.5              54.4              71.9
  Current smoking, % Physically inactive            13.9              31.8              20.5              13.2              6.1               21.9[^b^](#T2F2){ref-type="table-fn"}
  ≤3 times/week, %                                  71.7              81.8              78.0              70.3              66.8              75.0
  Income \< USD 20k, %                              15.3              13.6              13.7              16.9              13.9              18.8
  Education \< high school, %                       12.5              13.6              11.8              14.3              10.8              9.4
  Hypertension, %                                   56.9              77.3              50.3              59.4              57.3              53.1
  Diabetes, %                                       19.7              18.2              16.9              21.0              22.2              9.4
  Waist circumference, cm                           94.7 (15.0)       96.9 (12.3)       94.6 (15.3)       95.9 (15.3)       94.0 (15.1)       88.7 (9.7)
  BMI                                               28.7 (5.9)        30.3 (3.8)        28.1 (5.9)        29.3 (6.3)        28.5 (5.5)        27.6 (5.1)
  Calories, kcal                                    1,766 (761)       2,052 (826)       1,929 (795)       1,719 (797)       1,634 (631)       1,960 (760)[^b^](#T2F2){ref-type="table-fn"}
  eGFR, mL/min/1.73m^2^                             87 (70--99)       90 (67--110)      88 (69--100)      86 (69--98)       86 (72--97)       92 (72--104)
  ACR, mg/g                                         7.3 (4.5--14.6)   5.0 (3.3--11.5)   7.0 (4.1--12.7)   7.2 (4.9--14.0)   7.7 (4.4--18.4)   9.3 (4.4--23.7)
  CKD[^c^](#T2F3){ref-type="table-fn"}, %           22.4              18.2              19.3              23.9              24.6              15.6
  IL-6, pg/mL                                       2.8 (2.0--4.3)    3.2 (2.3--4.4)    2.9 (2.1--4.6)    2.9 (2.0--4.3)    2.8 (1.9--4.1)    2.5 (1.8--3.9)
  IL-8, pg/mL                                       2.5 (1.8--3.5)    2.4 (2.1--3.0)    2.4 (1.7--3.8)    2.5 (1.7--3.7)    2.6 (1.9--3.3)    2.2 (1.7--3.3)
  IL-10, pg/mL                                      9.3 (6.4--13.4)   9.1 (5.4--14.5)   9.3 (6.6--13.3)   9.4 (6.4--13.8)   9.4 (6.5--12.8)   7.8 (6.4--12.6)
  Fibrinogen, mg/dL                                 388 (337--455)    370 (333--451)    393 (340--473)    391 (339--447)    382 (335--443)    383 (325--482)
  CRP, mg/L                                         2.0 (0.9--4.9)    3.2 (1.7--11.8)   2.2 (0.9--5.1)    2.1 (0.9--5.2)    1.8 (0.8--4.4)    1.8 (0.7--5.7)
  WBC count, 1,000/µL                               5.5 (4.6--6.7)    6.2 (5.1--7.9)    5.6 (4.8--6.7)    5.6 (4.5--6.6)    5.5 (4.6--6.8)    5.6 (4.8--6.1)
  Cys C, mg/L                                       1.0 (0.8--1.1)    0.9 (0.8--1.1)    1.0 (0.8--1.1)    1.0 (0.8--1.2)    1.0 (0.8--1.2)    0.9 (0.8--1.1)

OBS, oxidative balance score; BMI, body mass index; eGFR, estimated glomerular filtration rate; ACR, albumin/creatinine ratio; CKD, chronic kidney disease; IL, interleukin; CRP, C-reactive protein; WBC, white blood cell; Cys C, cystatin C.

Values for age, waist circumference, BMI, and calories are reported as mean (±SD). Values for eGFR, ACR, IL-6, IL-8, IL-10, fibrinogen, CRP, WBC count, and Cys C are reported as median (IQR). Sex, race, current smoking status, income, education, hypertension, diabetes, and chronic kidney disease (CKD) are reported as percent.

*p* \< 0.05 based on the ANOVA, Kruskal-Wallis, or χ^2^ tests, as appropriate.

CKD was defined as eGFR \<60 mL/min/1.73m^2^ or albuminuria ≥30 mg/g.

###### 

Adjusted models[^a^](#T3F1){ref-type="table-fn"} showing the association between OBS (continuous and interval) and biomarkers of inflammation[^b^](#T3F2){ref-type="table-fn"} in the REGARDS cohort weighted random sample (*n* = 682)

                                                 IL-6          IL-8          IL-10         Fibrinogen   CRP           WBC count     Cys C
  ---------------------------------------------- ------------- ------------- ------------- ------------ ------------- ------------- ------------
  OBS[^c^](#T3F3){ref-type="table-fn"}           −6.4          −2.9          1.9           −0.2         −15.3         1.1           −0.9
  95% CI                                         −11.9, −0.5   −9.4, 4.1     −8.1, 13.0    −2.7, 2.5    −25.6, −3.6   −2.8, 5.2     −3.5, 1.8
  *p* value                                      0.03          0.4           0.7           0.9          0.01          0.6           0.5
                                                                                                                                    
  OBS                                                                                                                               
   Interval 1[^d^](#T3F4){ref-type="table-fn"}   \-            \-            \-            \-           \-            \-            \-
   Interval 2[^d^](#T3F4){ref-type="table-fn"}   3.7           2.0           15.3          5.7          −25.1         −1.3          −2.3
    95% CI                                       −18.7, 32.3   −22.4, 34.1   −23.2, 73.0   −4.6, 17.1   −55.2, 25.2   −14.8, 14.5   −12.2, 8.6
   Interval 3[^d^](#T3F4){ref-type="table-fn"}   −3.8          −1.5          23.5          2.9          −32.5         −0.8          −2.6
    95% CI                                       −24.4, 22.4   −24.9, 29.2   −17.4, 84.6   −7.0, 13.9   −59.5, 12.4   −14.4, 15.0   −12.4, 8.2
   Interval 4[^d^](#T3F4){ref-type="table-fn"}   −7.1          1.3           17.7          3.1          −39.0         3.2           −3.4
    95% CI                                       −27.4, 18.8   −23.2, 33.7   −22.0, 77.5   −7.1, 14.4   −63.8, 2.8    −11.3, 20.1   −13.3, 7.6
   Interval 5[^d^](#T3F4){ref-type="table-fn"}   −10.1         −14.0         10.5          6.7          −35.7         −5.7          −4.8
    95% CI                                       −33.5, 21.6   −38.7, 20.5   −33.0, 82.3   −5.9, 21.0   −65.8, 21.1   −21.7, 13.7   −16.5, 8.4
  *p* trend                                      0.06          0.5           0.9           0.9          0.05          0.6           0.4

OBS, oxidative balance score; IL, interleukin; CRP, C-reactive protein; WBC, white blood cell; Cys C, cystatin C; CI confidence interval.

Adjusted for age, sex, race, region, smoking status, BMI, protein, calories, NSAID, aspirin, and statin use.

Natural log transformed.

Estimates represent percent difference per 5-unit change in OBS.

Interval 1, OBS 0--5; interval 2, OBS 6--9; interval 3, OBS 10--13; interval 4, OBS 14--17; and interval 5, OBS 18--22.

\**p* \< 0.05 for interval.

###### 

Adjusted models[^a^](#T4F1){ref-type="table-fn"} showing the association between OBS and biomarkers of inflammation[^b^](#T4F2){ref-type="table-fn"}, stratified by CKD[^c^](#T4F3){ref-type="table-fn"}, in the REGARDS cohort weighted random sample (*n* = 682)

                                                 IL-6           IL-8           IL-10          Fibrinogen    CRP                                     WBC count     Cys C
  ---------------------------------------------- -------------- -------------- -------------- ------------- --------------------------------------- ------------- ---------------------------------------
  Interaction                                                                                                                                                     
   *p* value[^d^](#T4F4){ref-type="table-fn"}    0.03           0.3            0.03           0.09          0.2                                     0.5           \<0.001
                                                                                                                                                                  
  *CKD* (*n* = 153)                                                                                                                                               
  OBS[^e^](#T4F5){ref-type="table-fn"}           −0.1           14.7           −1.3           1.7           −11.4                                   10.7          1.7
   95% CI                                        −13.5, 15.4    0.3, 31.1      −26.7, 32.9    −3.7, 7.4     −32.4, 16.2                             −0.6, 23.3    −6.6, 10.7
  *p* value                                      0.9            0.04           0.9            0.5           0.4                                     0.06          0.7
  OBS                                                                                                                                                             
   Interval 1[^f^](#T4F6){ref-type="table-fn"}   \-             \-             \-             \-            \-                                      \-            \-
   Interval 2[^f^](#T4F6){ref-type="table-fn"}   −7.0           −2.2           −32.9          −13.1         −35.8                                   −7.6          −36.1\*
    95% CI                                       −49.7, 71.9    −43.7, 69.7    −79.5, 120.2   −30.4, 8.4    −78.7, 93.7                             −36.0, 33.3   −54.4, −10.4
   Interval 3[^f^](#T4F6){ref-type="table-fn"}   −16.6          4.8            40.8           −13.3         −56.2                                   −10.9         −37.5\*
    95% CI                                       −54.1, 51.5    −39.3, 80.8    −56.5, 356.1   −30.3, 7.7    −85.3, 30.5                             −37.5, 27.0   −55.3, −12.7
   Interval 4[^f^](#T4F6){ref-type="table-fn"}   −22.3          16.9           −6.8           −13.6         −54.6                                   10.8          −32.1[\*](#T4F7){ref-type="table-fn"}
    95% CI                                       −57.6, 42.3    −32.6, 102.9   −71.6, 205.7   −30.8, 7.7    −84.9, 36.9                             −23.8, 61.2   −51.6, −4.8
   Interval 5[^f^](#T4F6){ref-type="table-fn"}   31.9           59.0           −16.3          2.5           −35.0                                   4.0           −26.9
    95% CI                                       −41.7, 198.6   −24.1, 233.0   −83.0, 311.9   −23.9, 38.0   −85.2, 185.7                            −36.9, 71.4   −53.5, 15.0
  *p* for trend                                  0.5            0.05           0.9            0.9           0.3                                     0.06          0.6
                                                                                                                                                                  
  *No CKD* (*n* = 529)                                                                                                                                            
  OBS[^e^](#T4F5){ref-type="table-fn"}           −10.7          −3.9           7.5            −1.9          −19.6                                   −0.3          −1.1
    95% CI                                       −16.3, −4.7    −10.8, 3.6     −3.7, 19.9     −4.9, 1.0     −30.1, −7.5                             −4.3, 4.0     −3.1, 1.0
  *p* value                                      0.001          0.3            0.2            0.2           0.002                                   0.9           0.3
  OBS                                                                                                                                                             
   Interval 1[^f^](#T4F6){ref-type="table-fn"}   \-             \-             \-             \-            \-                                      \-            \-
   Interval 2[^f^](#T4F6){ref-type="table-fn"}   4.5            0.0            36.7           6.0           −37.4                                   −9.0          6.2
    95% CI                                       −19.3, 35.4    −25.8, 34.7    −11.5, 111.1   −6.1, 19.6    −64.2, 9.5                              −22.2, 6.4    −2.3, 15.5
   Interval 3[^f^](#T4F6){ref-type="table-fn"}   −4.9           −0.4           48.1           0.7           −45.0[\*](#T4F7){ref-type="table-fn"}   −8.6          4.6
    95% CI                                       −26.5, 23.0    −26.0, 34.1    −3.8, 128.0    −10.7, 13.5   −68.4, −4.1                             −21.9, 7.0    −3.7, 13.6
   Interval 4[^f^](#T4F6){ref-type="table-fn"}   −10.9          0.8            43.8           0.2           −50.4[\*](#T4F7){ref-type="table-fn"}   −5.0          4.6
    95% CI                                       −31.4, 15.9    −25.6, 36.4    −7.4, 123.3    −11.4, 13.4   −71.9, −12.6                            −19.1, 11.5   −5.6, 11.9
   Interval 5[^f^](#T4F6){ref-type="table-fn"}   −21.0          −16.8          53.5           2.6           −49.7[\*](#T4F7){ref-type="table-fn"}   −16.2         0.9
    95% CI                                       −42.4, 8.3     −42.1, 19.4    −9.3, 159.6    −11.3, 18.8   −74.4, −1.3                             −31.0, 1.7    −8.8, 11.5
  *p* trend                                      0.004          0.5            0.3            0.3           0.03                                    0.8           0.2

OBS, oxidative balance score; IL, interleukin; CRP, C-reactive protein; WBC, white blood cell; Cys C, cystatin C; CKD, chronic kidney disease; CI, confidence interval.

Adjusted for age, sex, race, region, smoking status, BMI, protein, calories, NSAID, aspirin, and statin use.

Natural log-transformed.

CKD was defined as eGFR\<60 mL/min/1.73m^2^ or albuminuria ≥30 mg/g.

*p* value for interaction based on continuous OBS.

Estimates represent percent difference per 5-unit change in OBS.

Interval 1, OBS 0--5; interval 2, OBS 6--9; interval 3, OBS 10--13; interval 4, OBS 14--17; interval 5, OBS 18--22.

*p* \< 0.05 for interval.
